Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Advanced Cancer Therapeutics Secures Exclusive License to Second Anti-Cancer Therapeutic from the University of Louisville's Brown Cancer Center
April 11th, 2008
Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, announced that it has signed an exclusive license to develop and market 4-IPP and its related compounds, discovered by scientists at the University of Louisville's James Graham Brown Cancer Center (Brown Cancer Center). Brown Cancer Center researchers Dr. Robert Mitchell and Dr. John Trent discovered that 4-IPP, a novel small molecule compound, exhibits anti-tumor activity by blocking tumor-specific angiogenesis, and thus far has demonstrated a favorable safety profile in laboratory studies. As a macrophage migration inhibitory factor (MIF), this...
Source: Health Business Week (2008-04-11)
|
